Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.
It is the first trial to use the pioneering genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together with a promising new medicine, called capivasertib.
The researchers used the drug combination to target two fundamental weaknesses in cancer at the same time – a damaged system for repairing DNA, and ‘addiction’ to a molecule called AKT which fuels tumour growth.
The early-stage trial, led by a team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, found that the drug combination was safe, successfully hit its targets, and was effective against a variety of advanced cancers – including those that had stopped responding to chemotherapy.
This combination is now planned to move forward into larger-scale trials. The study was published in the prestigious journal Cancer Discovery.
The Institute of Cancer Research (ICR) played a key role in pioneering both of the two precision medicines in the combination – discovering how to genetically target olaparib, and collaborating to create a precursor to capivasertib before the drug’s ultimate formulation by AstraZeneca.
The new study is an exemplar of the research the ICR will be doing in its revolutionary new Centre for Cancer Drug Discovery, which aims to use combination treatments to cut off cancer’s evolutionary pathways and overcome drug resistance.
In the phase I trial, researchers gave 64 patients with advanced solid tumours – including those with breast cancer, ovarian cancer and prostate cancers -combinations of olaparib and capivasertib.
The combination was well tolerated, and 25 of the 56 patients whose response could be assessed – or 45 per cent – benefited from treatment, with their tumours either shrinking or stopping growing.
Some of these patients had previously stopped responding to chemotherapy and other targeted treatments as their cancers became drug resistant.
Many of the patients who responded to the treatment had mutations to genes involved in repairing DNA, including to the BRCA genes.
The trial was funded by the pharmaceutical company AstraZeneca, under the auspices of the Cancer Research UK Experimental Cancer Medicine Centre Combinations Alliance.
The findings provide early clinical evidence that olaparib and capivasertib have the potential to work well as a combination treatment and could improve outcomes for some patients with drug-resistant cancer.
The team are now planning further, later-stage clinical trials to assess the drug combination’s benefit and to study its effect in patients whose tumours do not have faults in the AKT gene or related to DNA repair.
The ICR is the most successful academic institution in the world at discovering cancer drugs – having discovered 20 new drug candidates since 2005. The ICR is nearing completion of a new Centre for Cancer Drug Discovery, and is now raising money for the state-of-the-art equipment its scientists will need to get their work in the building off to the strongest possible start.
Study leader Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:
“Our study establishes the potential of a combination of two precision medicines for patients whose tumours have stopped responding to existing drugs. The combination of olaparib and capivasertib works by attacking two fundamental weaknesses in cancer, and could potentially be used to treat patients with several common tumours. I look forward to seeing the possible benefit of the combination tested in later-stage trials.”
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“This new clinical trial is a terrific example of how we can now translate scientific discoveries about the biology of cancer cells into innovative new cancer treatments with real benefits for patients. It’s also an example of the pioneering strategy we have adopted at the ICR of targeting cancer evolution and drug resistance – often through the use of combination treatments to hit multiple targets at once and block off escape routes, just as is done with diseases like HIV.
“It’s very exciting to see two drugs pioneered thanks to the ICR’s research now being used together in patients, with the real possibility that they could offer an urgently needed new treatment option for patients whose cancers have become resistant to current treatments.”
###
Notes to Editors
For more information please contact Sarah Wells in the ICR press office on 020 7153 5582 or sarah.wells@icr.ac.uk. For enquiries out of hours, please call 07595 963 613.
Olaparib is a type of drug called a PARP inhibitor, which is licensed for patients with ovarian, breast and prostate cancers who have mutations in the BRCA genes, or in the case of prostate cancer to other genes involved in DNA repair.
The PARP protein helps damaged cells to repair themselves and some cancer cells, including those with BRCA mutations, need it to keep their DNA healthy. When olaparib stops PARP from repairing DNA damage, the cancer cells die.
Olaparib has proven to be effective for patients whose cancers have defects to DNA repair, but often drug resistance emerges limiting its long-term use. Combination treatments with drugs like capivasertib could help to overcome resistance.
Capivasertib is a targeted inhibitor of the cancer-driving protein AKT, a key node in a signalling network that becomes dysregulated in a range of cancers and helps to drive the disease. Cancer cells become so reliant on AKT for their growth that they are described as becoming addicted to it.
ICR scientists revealed the 3D structure of AKT before researchers at the ICR’s Cancer Research UK Therapeutics Unit, working in collaboration with the company Astex, discovered precursors to the drug.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top centres for cancer research and treatment globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
A college of the University of London, the ICR is the UK’s top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR’s mission is to make the discoveries that defeat cancer.
For more information visit //www.